N/A N=37 Investigation of the Performance of Ostomy Base Plate
Ileostomy - Stoma
Primary: Leakage Under the Base Plate — 8.2; 5.5; 8.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=28 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Responder Rate — 60.7; 63.6 percentage of responders
N/A N=301 Tocolysis for Preterm Labor
Preterm Labor
Primary: The Primary Outcome Measure of This Research is to Compare the Efficacy of the Three Clinically Used Tocolytic Agents in a Prospective Study That Will Allow Direct…
Phase 3 N=803 Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) — -0.89; -0.42; -0.70; -0.29 percentage of glycosylated hemoglobin
Phase 4 N=31 Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine
Bipolar Disorder · Weight Gain
Primary: Change in Body Mass Index (BMI) — 0.8; 1.8 kg/m2
Phase 4 N=78 MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.21 units on a scale — p=<0.0001
N/A N=263 Advisa MRI Clinical Study
Magnetic Resonance Imaging · Cardiac Pacemaker, Artificial
Primary: Magnetic Resonance Imaging (MRI)-Related Complications — 0 participants — p=<0.0001
Phase 2 N=32 Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival (PFS) — 3.1 percentage of participants
Phase 2 N=92 Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
Chronic Ischemic Heart Disease · Left Ventricular Dysfunction · Angina
Primary: Change in Maximal Oxygen Consumption (VO2max) — -0.6; 0.4 mL/kg/min — p=0.169
N/A N=87 The Efficiency of the Hair2Go Device: A Prospective, Open, Label Study With Before-After Design
Hair Removal
Primary: Hair Clearance 1 Month After Last Treatment — 56.83; 54.08 %baseline hair count
Phase 2 N=41 Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Prostate Cancer
Primary: Protein-specific Antigen (PSA) Response Rate — 3 percentage of patients
Phase 2 N=120 Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 3.5; 4.4; 2.8; 1.7 percentage of ejection fraction — p=0.959
Phase 3 N=84 LapBand Adjustment to Improve Early Weight Loss
Obesity
Primary: %Excess Weight Loss 4-6 Weeks After Surgery (Large and Small Bands) — 15.63; 20.8 %EWL
Phase 3 N=1,554 Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis) — -0.89; -1.43; -1.42 percentage of glycosylated hemoglobin — p=<0.001
Phase 3 N=255 Sudden Deafness Treatment Trial
Sudden Deafness
Primary: Hearing Improvement — 30.7; 28.7 dB